Making innovation your routine
The standalone mid-throughput cobas t 511 coagulation analyzer aids in the diagnosis of coagulation abnormalities and in monitoring anticoagulant therapy.
Today's coagulation lab needs to meet clinicians' demand for fast and accurate results and cost effective solutions for a large number of routine coagulation parameters.
By delivering high processing power, seamless workflow dynamics, and unique walk away reagent management (W.A.R.M) with smart sample handling, we answer your need for maximized workflow efficiency and reliable results. Empowering you to support the best outcome for your patients.
With the high processing power and extensive menu, the cobas t 511 coagulation analyzer enables laboratories to complete their daily testing workload fast
The cobas t 511 coagulation analyzer offers ease of use, continuous operation and maximized productivity, while ensuring operator safety and reliable results to help support better patient care. These benefits are enabled through:
The cobas t 511 coagulation analyzer is capable of fully automated and scheduled reagent reconstitution - the ultimate enabler of continuous operation. This innovative and convenient concept minimizes user error risks, and ensures the optimized use and high quality of reagents.
Because one size does not fit all, Roche offers two different options to benefit from the innovation brought to coagulation testing: the mid-throughput cobas t 511 coagulation analyzer, and the high-throughput cobas t 711 coagulation analyzer.
Antithrombin
In vitro assay for the quantitative determination of antithrombin activity in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of antithrombin deficiency.
Anti-Xa
In vitro assay for the quantitative determination of the anti-Xa activity of unfractionated (UFH) and low molecular weight (LMWH) heparins in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the management of anti-Xa Heparin therapy.
APC Resistance
APC Resistance is a functional assay for the determination of resistance of factor Va to inactivation by activated protein C (APC) caused by the factor V Leiden mutation (FV:R506Q) in citrated plasma on indicated cobas t analyzers.
aPTT
In vitro assay, with reduced lupus sensitivity, for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.
aPTT Lupus
In vitro assay, with increased lupus sensitivity, for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.
aPTT Screen
In vitro assay for the determination of activated partial thromboplastin time (aPTT) in citrated plasma on the indicated cobas t analyzers. The aPTT is used to evaluate the intrinsic coagulation pathway.
D-Dimer
In vitro assay for the quantitative immunological determination of fibrin degradation products (D‑dimer and X‑oligomers) in human citrated plasma on the indicated cobas t analyzers. In conjunction with a non-high clinical probability assessment, a normal D‑dimer result (< 0.5 μg FEUa)/mL) is intended as an aid in the exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Fibrinogen
In vitro assay for the quantitative determination of fibrinogen (Clauss method) in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the detection of hypo- and hyperfibrinogenemia, dysfibrinogenemia and afibrinogenemia.
FII
Human plasma immunodepleted of Factor II for the quantitative determination of Factor II activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.
Free Protein S
In vitro assay for the quantitative determination of free protein S in human citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired protein S deficiency.
FV
Human plasma immunodepleted of Factor V for the quantitative determination of Factor V activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.Human plasma immunodepleted of Factor II for the quantitative determination of Factor II activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.
FVII
Human plasma immunodepleted of Factor VII for the quantitative determination of Factor VII activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.
FVIII
Human plasma immunodepleted of Factor VIII for the quantitative determination of Factor VIII activity in citrated plasma, based on the activated partial thromboplastin time (aPTT) assay, on the indicated cobas t analyzers.
FX
Human plasma immunodepleted of Factor X for the quantitative determination of Factor X activity in citrated plasma, based on the prothrombin time (PT) assay, on the indicated cobas t analyzers.
HIL Test
In vitro test for the semi-quantitative determination of the lipemia index, hemolysis index and icterus index in citrated plasma on cobas t systems.
Lupus S, Lupus C
In vitro assays to screen for (Lupus S) and to confirm (Lupus C) the presence of lupus anticoagulants in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of anti‑phospholipid syndrome.
PT derived Fibrinogen
The derived fibrinogen result is intended as an aid in the diagnosis of a fibrinogen deficiency.
Protein C Chromogenic
In vitro chromogenic assay for the quantitative determination of Protein C activity in citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired Protein C deficiencies.
PT Owren
In vitro assay for the determination of the Owrens prothrombin time in citrated plasma on the indicated cobas t analyzers. The Owrens prothrombin time is intended as an aid in the management of vitamin K antagonist therapy.
PT Rec
In vitro assay for the determination of prothrombin time and derived fibrinogen in citrated plasma on the indicated cobas t analyzers. The prothrombin time is used for evaluation of the extrinsic coagulation pathway and as an aid in the management of vitamin K antagonist therapy. The derived fibrinogen result is intended as an aid in the diagnosis of a fibrinogen deficiency.
Thrombin Time
In vitro assay for the determination of Thrombin Time (TT) in human citrated plasma on the indicated cobas t analyzers.s.
vWF Act
In vitro assay for the quantitative determination of platelet glycoprotein Ib binding activity of von Willebrand factor in human citrated plasma on the indicated cobas t analyzers. The assay is intended as an aid in the diagnosis of inherited and acquired von Willebrand Disease (vWD).
Information taken from respective method sheets
